Cross-Sector entity
The Goldman Sachs Group is most often covered alongside Citigroup, which appears in 3 of these 5 stories. The 39-day window averages about 0.9 stories each week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 2 of those 5, with the remainder spread across 3 other categories.
5 verified stories tracked
Last mentioned: Aug 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The Goldman Sachs Group is most often covered alongside Citigroup, which appears in 3 of these 5 stories. The 39-day window averages about 0.9 stories each week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 2 of those 5, with the remainder spread across 3 other categories. Negative sentiment appears in 0% of the tracked stories. Each carries 2 original sources on average. We currently track 5 Cross-Sector stories that mention The Goldman Sachs Group, published between July 10, 2026 and August 17, 2026.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering The Goldman Sachs Group. Shared-story counts are live from our verified record — not editorial picks.
Mitsubishi UFJ's Q2 13F shows a 22.3% reduction in Nike and 6.4% in Zoetis, just as sell-side targets on NKE cluster at $42–$47. For finance professionals, the filings highlight institutional rebalancing, ownership concentration, and analyst caution as key sentiment signals.
Source: Ticker Report · Watch List News
Globant reported EPS of $1.40, missing consensus by $0.10, while revenue of $614.42 million slightly beat estimates but was flat year over year. Shares fell 8.9% to $37.35 as analysts lowered price targets. The company reiterated FY2026 EPS guidance of $5.75-$6.15 and Q3 guidance of $1.43.
Source: themarketsdaily.com · dailypolitical.com
Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
Wells Fargo’s $225 target is the lowest among major banks, yet ResMed’s average analyst target of $270.64 implies a 23.2% upside. Markets weigh defensive balance sheet qualities against emerging therapeutic competition.
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
